Katia M S Gomes1, Juliane C Campos1, Luiz R G Bechara1, Bruno Queliconi2, Vanessa M Lima1, Marie-Helene Disatnik3, Paulo Magno4, Che-Hong Chen3, Patricia C Brum5, Alicia J Kowaltowski2, Daria Mochly-Rosen3, Julio C B Ferreira6. 1. Department of Anatomy, Institute of Biomedical Sciences, Paulo, Brazil. 2. Departamento de Bioquímica, Instituto de Química, Paulo, Brazil. 3. Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA. 4. Heart Institute, Paulo, Brazil. 5. School of Physical Education and Sports, University of Sao Paulo, Paulo, Brazil. 6. Department of Anatomy, Institute of Biomedical Sciences, Paulo, Brazil Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA jcesarbf@usp.br.
Abstract
AIMS: We previously demonstrated that pharmacological activation of mitochondrial aldehyde dehydrogenase 2 (ALDH2) protects the heart against acute ischaemia/reperfusion injury. Here, we determined the benefits of chronic activation of ALDH2 on the progression of heart failure (HF) using a post-myocardial infarction model. METHODS AND RESULTS: We showed that a 6-week treatment of myocardial infarction-induced HF rats with a selective ALDH2 activator (Alda-1), starting 4 weeks after myocardial infarction at a time when ventricular remodelling and cardiac dysfunction were present, improved cardiomyocyte shortening, cardiac function, left ventricular compliance and diastolic function under basal conditions, and after isoproterenol stimulation. Importantly, sustained Alda-1 treatment showed no toxicity and promoted a cardiac anti-remodelling effect by suppressing myocardial hypertrophy and fibrosis. Moreover, accumulation of 4-hydroxynonenal (4-HNE)-protein adducts and protein carbonyls seen in HF was not observed in Alda-1-treated rats, suggesting that increasing the activity of ALDH2 contributes to the reduction of aldehydic load in failing hearts. ALDH2 activation was associated with improved mitochondrial function, including elevated mitochondrial respiratory control ratios and reduced H2O2 release. Importantly, selective ALDH2 activation decreased mitochondrial Ca(2+)-induced permeability transition and cytochrome c release in failing hearts. Further supporting a mitochondrial mechanism for ALDH2, Alda-1 treatment preserved mitochondrial function upon in vitro aldehydic load. CONCLUSIONS: Selective activation of mitochondrial ALDH2 is sufficient to improve the HF outcome by reducing the toxic effects of aldehydic overload on mitochondrial bioenergetics and reactive oxygen species generation, suggesting that ALDH2 activators, such as Alda-1, have a potential therapeutic value for treating HF patients. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: We previously demonstrated that pharmacological activation of mitochondrial aldehyde dehydrogenase 2 (ALDH2) protects the heart against acute ischaemia/reperfusion injury. Here, we determined the benefits of chronic activation of ALDH2 on the progression of heart failure (HF) using a post-myocardial infarction model. METHODS AND RESULTS: We showed that a 6-week treatment of myocardial infarction-induced HF rats with a selective ALDH2 activator (Alda-1), starting 4 weeks after myocardial infarction at a time when ventricular remodelling and cardiac dysfunction were present, improved cardiomyocyte shortening, cardiac function, left ventricular compliance and diastolic function under basal conditions, and after isoproterenol stimulation. Importantly, sustained Alda-1 treatment showed no toxicity and promoted a cardiac anti-remodelling effect by suppressing myocardial hypertrophy and fibrosis. Moreover, accumulation of 4-hydroxynonenal (4-HNE)-protein adducts and protein carbonyls seen in HF was not observed in Alda-1-treated rats, suggesting that increasing the activity of ALDH2 contributes to the reduction of aldehydic load in failing hearts. ALDH2 activation was associated with improved mitochondrial function, including elevated mitochondrial respiratory control ratios and reduced H2O2 release. Importantly, selective ALDH2 activation decreased mitochondrial Ca(2+)-induced permeability transition and cytochrome c release in failing hearts. Further supporting a mitochondrial mechanism for ALDH2, Alda-1 treatment preserved mitochondrial function upon in vitro aldehydic load. CONCLUSIONS: Selective activation of mitochondrial ALDH2 is sufficient to improve the HF outcome by reducing the toxic effects of aldehydic overload on mitochondrial bioenergetics and reactive oxygen species generation, suggesting that ALDH2 activators, such as Alda-1, have a potential therapeutic value for treating HF patients. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Shahid P Baba; Deqing Zhang; Mahavir Singh; Sujith Dassanayaka; Zhengzhi Xie; Ganapathy Jagatheesan; Jingjing Zhao; Virginia K Schmidtke; Kenneth R Brittian; Michael L Merchant; Daniel J Conklin; Steven P Jones; Aruni Bhatnagar Journal: J Mol Cell Cardiol Date: 2018-04-05 Impact factor: 5.000
Authors: Antje D Ebert; Kazuki Kodo; Ping Liang; Haodi Wu; Bruno C Huber; Johannes Riegler; Jared Churko; Jaecheol Lee; Patricia de Almeida; Feng Lan; Sebastian Diecke; Paul W Burridge; Joseph D Gold; Daria Mochly-Rosen; Joseph C Wu Journal: Sci Transl Med Date: 2014-09-24 Impact factor: 17.956
Authors: Cintia B Ueta; Katia S Gomes; Márcio A Ribeiro; Daria Mochly-Rosen; Julio C B Ferreira Journal: Pharmacol Res Date: 2016-11-19 Impact factor: 7.658
Authors: Courtney Cates; Thomas Rousselle; Jinli Wang; Nanhu Quan; Lin Wang; Xu Chen; Likui Yang; Alireza R Rezaie; Ji Li Journal: Biochem Biophys Res Commun Date: 2017-12-27 Impact factor: 3.575
Authors: Jingjing Zhao; Dheeraj Kumar Posa; Vijay Kumar; David Hoetker; Amit Kumar; Smirthy Ganesan; Daniel W Riggs; Aruni Bhatnagar; Michael F Wempe; Shahid P Baba Journal: Amino Acids Date: 2018-11-17 Impact factor: 3.520